In vivo engineering of B7-H3 CAR-T cells for ovarian cancer therapy
Official title: SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy
Funded at Mucommune, LLC · NIH-11413779 · Data updated 2026-11-12
A patient-focused look at a new, in-body CAR-T cell therapy designed to target ovarian cancer by engineering T cells directly inside the body to fight tumors.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | September 11, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,025,819 |
| NIH project number | 5R44CA306674-02 |
| Project ID | NIH-11413779 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with ovarian cancer who express the B7-H3 antigen and are eligible for CAR-T based therapies.
✕Less likely to help
Patients without the B7-H3 target or those not suitable for in vivo CAR-T approaches may not benefit.
What this research studies
This grant supports developing a way to create CAR-T cells inside the patient’s body rather than in a lab, with the goal of faster, cheaper treatment that can reach solid tumors like ovarian cancer. The approach uses a specialized viral system to modify circulating T cells so they can attack cancer cells expressing B7-H3. The work aims to show that this in vivo method can produce effective CAR-T cells against ovarian cancer while avoiding lengthy ex vivo cell processing. If successful, it could broaden access to CAR-T therapy and reduce time between treatment decision and administration.
Why it matters
Potential benefit: If successful, patients could receive CAR-T therapy more quickly and potentially at lower cost, with expanded options for ovarian cancer treatment.
How similar studies have gone: Early in vivo CAR-T approaches have shown promise in preclinical models, but human data remain limited and this remains a novel strategy.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Yang, Ming — Mucommune, LLC
- Study coordinator: Yang, Ming
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.